A biopharmaceutical company developing therapeutics based on RNA interference, or RNAi. It is building a broad pipeline of RNAi therapeutics; its most advanced programme is in Phase II human clinical trials for the treatment of respiratory syncytial virus (RSV) infection and is partnered with Cubist and Kyowa Hakko. In addition, the company is developing RNAi therapeutics for the treatment of a wide range of disease areas, including liver cancers, hypercholesterolemia, Huntington's disease, and TTR amyloidosis.